Protalix BioTherapeutics, Inc. Share Price
PLXProtalix BioTherapeutics, Inc. Stock Performance
Open $2.08 | Prev. Close $2.06 | Circuit Range N/A |
Day Range $2.08 - $2.10 | Year Range $1.32 - $3.10 | Volume 32,247 |
Average Traded $2.09 |
Protalix BioTherapeutics, Inc. Share Price Chart
About Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.
Protalix BioTherapeutics, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
20-Jan-26 | $2.03 | $2.04 | +0.54% |
16-Jan-26 | $2.06 | $2.03 | -1.50% |
15-Jan-26 | $2.07 | $2.06 | +0.00% |
14-Jan-26 | $2.02 | $2.06 | +1.73% |
13-Jan-26 | $2.12 | $2.02 | -3.57% |
12-Jan-26 | $2.08 | $2.10 | +2.44% |
09-Jan-26 | $2.03 | $2.05 | +2.50% |